Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03298087 · ClinicalTrials.gov registry record · Phase 2
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
A Phase 2 study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT03298087: Completed Phase 2 study, sponsored by VA Office of Research and Development.
NCT03298087 is a Phase 2 study that has completed, run by VA Office of Research and Development. The registered enrollment target is 28 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03298087, a Phase 2 study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is a trial for patients with newly diagnosed metastatic prostate cancer with 5 or fewer sites of metastases. The trial involves surgery (removal of the prostate) or radiation to the prostate, six months of hormone therapy, and stereotactic body radiotherapy to the sites of metastasis.
Primary Outcome
PSA is a biomarker for disease burden in prostate adenocarcinoma and offers a non-invasive and sensitive assessment of disease control after treatment in the vast majority of patients.
Interventions
- RADIATION stereotactic body radiotherapy
- DRUG Leuprolide
- DRUG apalutamide
- PROCEDURE radical prostatectomy
- DRUG abiraterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-07-01 |
| Est. Completion | 2024-03-31 |
| Phase | Phase 2 |
What the finished NCT03298087 record still lists
NCT03298087 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 5 interventions - of which stereotactic body radiotherapy is the first listed.
NCT03298087 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03298087 about?
NCT03298087 is a clinical study titled "Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer". This is a trial for patients with newly diagnosed metastatic prostate cancer with 5 or fewer sites of metastases. The trial involves surgery (removal of the prostate) or radiation to the prostate, six months of hormone therapy, and stereotactic body radiotherapy to the sites of metastasis.
What is the current status of trial NCT03298087?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2018-07-01. Estimated completion is 2024-03-31.
What interventions are being tested in trial NCT03298087?
The interventions under investigation include: stereotactic body radiotherapy (RADIATION), Leuprolide (DRUG), apalutamide (DRUG), radical prostatectomy (PROCEDURE), abiraterone (DRUG).
Who is sponsoring clinical trial NCT03298087?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03298087's enrollment target sits among peer trials
28 1677th of 2000 higher than 304 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI